Eilean Therapeutics Presents First-in-Class MALT1 Degrader TE205 Demonstrating In Vivo Efficacy in Ulcerative Colitis at the 4th International Conference on Microbiology and Immunology

DOVER, Del., Nov. 4, 2025 /PRNewswire/ -- Eilean Therapeutics LLC, a biopharmaceutical company dedicated to developing best-in-class and first-in-class small-molecule therapies targeting genetic escape mutations in cancer and advancing innovative treatments for chronic inflammatory and...